PharmaLundensis AB:医療機器:M&Aディール及び事業提携情報

◆英語タイトル:PharmaLundensis AB - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C11419
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
PharmaLundensis AB (PharmaLundensis) is a pharmaceutical company that develops drugs for lung diseases. The company develops drugs for chronic obstructive pulmonary disease (COPD), chronic bronchitis and influenza-induced lung failure. It also develops EcoFilter, a system that that eliminates all the release of pharmaceutical drugs and multi-resistant bacteria in hospital waste water and removes all multi-resistant bacteria from hospital sewage pipes, thereby eliminating the risk of multi-resistant bacteria that are growing in the pipes can infect patients in the hospital wards. The company conducts research on lung physiology and pathology to ascertain pharmacological modification applications to treat pulmonary diseases. PharmaLundensis is headquartered in Lund, Sweden.

PharmaLundensis AB – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
PharmaLundensis AB, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
PharmaLundensis AB, Medical Equipment Deals By Type, 2012 to YTD 2018 6
PharmaLundensis AB, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
PharmaLundensis AB, Medical Equipment, Deals By Market, 2012 to YTD 2018 8
PharmaLundensis AB, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
PharmaLundensis AB, Medical Equipment, Deal Details 10
Equity Offering 10
PharmaLundensis to Raise USD1.2 Million in Rights Offering of Shares 10
PharmaLundensis Raises USD0.9 Million in Public Offering of Shares 11
PharmaLundensis Raises USD0.4 Million in Public Offering of Shares 12
PharmaLundensis AB – Key Competitors 13
PharmaLundensis AB – Key Employees 14
PharmaLundensis AB – Locations And Subsidiaries 15
Head Office 15
Recent Developments 16
Financial Announcements 16
Feb 16, 2018: PharmaLundensis: Financial Statement 1 January 2017 to 31 December 2017 16
May 24, 2017: PharmaLundensis: Annual Report 2016 17
Product News 19
Jun 01, 2017: PharmaLundensis: Publication of EcoFilter Patent Application 1 + 2 19
May 02, 2017: Development and patenting of systems to eliminate all drug emissions 20
Mar 03, 2017: New positive review report from PRV for EcoFilter 21
Feb 09, 2017: Positive International PCT Review for EcoFilter Patent 22
Feb 06, 2017: EcoFilter patent approved in Sweden 23
Other Significant Developments 24
Jul 13, 2017: Pharmalundensis: Valuation of the project’s economic potential 24
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25

List of Tables
PharmaLundensis AB, Medical Equipment, Key Facts 2
PharmaLundensis AB, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
PharmaLundensis AB, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
PharmaLundensis AB, Medical Equipment Deals By Type, 2012 to YTD 2018 6
PharmaLundensis AB, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
PharmaLundensis AB, Deals By Market, 2012 to YTD 2018 8
PharmaLundensis AB, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
PharmaLundensis to Raise USD1.2 Million in Rights Offering of Shares 10
PharmaLundensis Raises USD0.9 Million in Public Offering of Shares 11
PharmaLundensis Raises USD0.4 Million in Public Offering of Shares 12
PharmaLundensis AB, Key Competitors 13
PharmaLundensis AB, Key Employees 14

List of Figures
PharmaLundensis AB, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
PharmaLundensis AB, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
PharmaLundensis AB, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
PharmaLundensis AB, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
PharmaLundensis AB, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
PharmaLundensis AB, Medical Equipment, Deals by Type, 2012 to YTD 2018 6
PharmaLundensis AB, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
PharmaLundensis AB, Medical Equipment, Deals by Market, 2012 to YTD 2018 8

★海外企業調査レポート[PharmaLundensis AB:医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Blue Moon Zinc Corp.:企業の戦略・SWOT・財務情報
    Blue Moon Zinc Corp. - Strategy, SWOT and Corporate Finance Report Summary Blue Moon Zinc Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Stockmann plc (STCBV):企業の財務・戦略的SWOT分析
    Stockmann plc (STCBV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Allergan Plc (AGN)-医療機器分野:企業M&A・提携分析
    Summary Allergan Plc (Allergan) is a specialty pharmaceutical company that develops and sells branded pharmaceuticals, biosimilar and over-the-counter (OTC) pharmaceutical products. It offers products in the areas of eye care, medical aesthetics, dermatology, central nervous system, gastroenterology …
  • Oneok Inc (OKE):企業の財務・戦略的SWOT分析
    Oneok Inc (OKE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • SpringWorks Therapeutics LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary SpringWorks Therapeutics LLC (SpringWorks Therapeutics) is a drug development company that develops therapeutic medicines for various diseases. The company’s pipeline products include Nirogacestat, MEK ½ Inhibitor, Senicapoc and FAAH Inhibitor. Its Nirogacestat is a gamma secretase inhibitor …
  • Pacgen Life Science Corp (PBS):企業の財務・戦略的SWOT分析
    Summary Pacgen Life Science Corp (Pacgen), formerly Pacgen Biopharmaceuticals Corp, is a life science technology company that develops and commercializes biomedical products and services. The company offers development of novel therapeutic drug candidates. It provides product such as include amino-a …
  • Alphabet Inc:企業のM&A・事業提携・投資動向
    Alphabet Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Alphabet Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • UMW Holdings Bhd (UMW)
    UMW Holdings Bhd (UMW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • View Inc:電力:M&Aディール及び事業提携情報
    Summary View Inc (View), formerly Soladigm, Inc. is a clean technology company that offers smart glass systems. The company’s View Dynamic Glass controls light and heat entering the building. View Dynamic Glass uses intelligent engine that adapts to the environment, responds to users’ preferences an …
  • Bandera Electric Cooperative, Inc.:企業の戦略的SWOT分析
    Bandera Electric Cooperative, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Immune Pharmaceuticals Inc (IMNP):企業の財務・戦略的SWOT分析
    Summary Immune Pharmaceuticals Inc (Immune Pharma) formerly EpiCept Corp is a drug development company that develops novel therapies for immunologic and inflammatory diseases. The company’s pipeline products include Bertilimumab and Nanocyclo. Its Bertilimumab is a human monoclonal antibody designed …
  • RBC Wealth Management:企業の戦略・SWOT・財務分析
    RBC Wealth Management - Strategy, SWOT and Corporate Finance Report Summary RBC Wealth Management - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Interpace Diagnostics Group Inc (IDXG)-製薬・医療分野:企業M&A・提携分析
    Summary Interpace Diagnostics Group Inc (Interpace Diagnostics), formerly PDI Inc, is a developer of molecular diagnostics tests. The company offers PancraGen, a DNA based molecular test that aids in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its pathfinder platform; a …
  • China North Industries Corporation:企業の戦略・SWOT・財務情報
    China North Industries Corporation - Strategy, SWOT and Corporate Finance Report Summary China North Industries Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Compass Minerals International Inc (CMP):企業の財務・戦略的SWOT分析
    Compass Minerals International Inc (CMP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Spectral Medical Inc (EDT):企業の財務・戦略的SWOT分析
    Summary Spectral Medical Inc (Spectral), formerly Spectral Diagnostics Inc, is a biotechnology company that develops and commercializes diagnostic solutions for patient management. The company’s products comprise EAA, PMX, SAMI, toraymyxin and reagents. Its EAA is an endotoxin activity assay, which …
  • PsychoGenics Inc-製薬・医療分野:企業M&A・提携分析
    Summary PsychoGenics Inc (PsychoGenics) is an preclinical contract research organization that offers contract research, standard and customized preclinical services and drug discovery services. The organization offers various behavioral tests to drug candidates in the areas of pain and inflammation, …
  • Orient Europharma Co Ltd (4120):企業の財務・戦略的SWOT分析
    Summary Orient Europharma Co Ltd (OEP) is a pharmaceutical company that manufactures and markets prescription medication, Innovative medical and Infant health products. The company’s prescription medication products include cardiovascular medication, immunology medicine, metabolism medicine, neurolo …
  • Athenex Inc (ATNX):製薬・医療:M&Aディール及び事業提携情報
    Summary Athenex Inc (Athenex), formerly Kinex Pharmaceuticals LLC, is a biopharmaceutical company focused on the discovery, development and commercialization novel medicines and cell therapies for the treatment of cancers. The company’s orascovery products candidates include oral formulations of pac …
  • DePuy Synthes Inc:企業の製品パイプライン分析2018
    Summary DePuy Synthes Inc (DePuy Synthes), a subsidiary of Johnson & Johnson, is a medical device company that provides products for orthopedic and neurological procedures. DePuy Synthes operates through eight divisions: joint reconstruction, sports medicine, neurological, spine, trauma, cranio-maxi …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆